Log-Rank Test vs MaxCombo and Difference in Restricted Mean Survival Time Tests for Comparing Survival Under Nonproportional Hazards in Immuno-oncology Trials: A Systematic Review and Meta-analysis.

JAMA Oncol · 2022 · PMC9305601 · PMID 35862037

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

failed to reach statistical significanceno p-value reported

Although dRMST was concordant with log-rank test in most cases, in the 5 cases where dRMST differed from log-rank test and failed to reach statistical significance, the overall survival benefit appeared clinically meaningful with HR ranging from 0.58-0.83.

also in 6,035 other papers

nominally significantno p-value reported

Between the log-rank and dRMST tests, 137 of 150 comparisons (91%) were concordant; log-rank was nominally significant in 5 of 13 cases, while dRMST was significant in 8 of 13.

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.